Recro Pharma (REPH) Tops Q1 EPS by 5c, Revenue Beats

Recro Pharma (NASDAQ: REPH) reported Q1 EPS of ($0.65), $0.05 better than the analyst estimate of ($0.70). Revenue for the quarter came in at $19.54 million versus the consensus estimate of $17.74 million.

For earnings history and earnings-related data on Recro Pharma (REPH) click here.

You May Also Be Interested In

• Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
• Birchtech Corp. (BCHT) Misses Q2 EPS by 7c
• Eikon Therapeutics, Inc. (EIKN) Misses Q2 EPS by 163c